BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 25648357)

  • 41. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
    Redjal N; Reinshagen C; Le A; Walcott BP; McDonnell E; Dietrich J; Nahed BV
    J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
    Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
    Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular dissection of the valproic acid effects on glioma cells.
    Hoja S; Schulze M; Rehli M; Proescholdt M; Herold-Mende C; Hau P; Riemenschneider MJ
    Oncotarget; 2016 Sep; 7(39):62989-63002. PubMed ID: 27556305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments.
    Merz F; Gaunitz F; Dehghani F; Renner C; Meixensberger J; Gutenberg A; Giese A; Schopow K; Hellwig C; Schäfer M; Bauer M; Stöcker H; Taucher-Scholz G; Durante M; Bechmann I
    Neuro Oncol; 2013 Jun; 15(6):670-81. PubMed ID: 23576601
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme.
    Tomuleasa C; Soritau O; Kacso G; Fischer-Fodor E; Cocis A; Ioani H; Timis T; Petrescu M; Cernea D; Virag P; Irimie A; Florian IS
    J BUON; 2010; 15(4):758-62. PubMed ID: 21229642
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
    Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
    Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
    Huang H; Lin H; Zhang X; Li J
    Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma.
    Adeberg S; Bostel T; Harrabi S; Bernhardt D; Welzel T; Wick W; Debus J; Combs SE
    BMC Cancer; 2015 Jul; 15():558. PubMed ID: 26223282
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.
    Mellai M; Cattaneo M; Storaci AM; Annovazzi L; Cassoni P; Melcarne A; De Blasio P; Schiffer D; Biunno I
    Oncotarget; 2015 May; 6(14):12452-67. PubMed ID: 25948789
    [TBL] [Abstract][Full Text] [Related]  

  • 50. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
    Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
    Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
    Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
    Beauchesne P; Quillien V; Faure G; Bernier V; Noel G; Quetin P; Gorlia T; Carnin C; Pedeux R
    Int J Cancer; 2016 Mar; 138(6):1538-44. PubMed ID: 26501997
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
    Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM
    Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
    Castro-Gamero AM; Borges KS; Moreno DA; Suazo VK; Fujinami MM; de Paula Gomes Queiroz R; de Oliveira HF; Carlotti CG; Scrideli CA; Tone LG
    Invest New Drugs; 2013 Aug; 31(4):858-70. PubMed ID: 23299390
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53.
    Nie E; Jin X; Wu W; Yu T; Zhou X; Zhi T; Shi Z; Zhang J; Liu N; You Y
    Sci Rep; 2016 Dec; 6():39743. PubMed ID: 28000777
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of valproic acid on the outcome of glioblastoma multiforme.
    Tsai HC; Wei KC; Tsai CN; Huang YC; Chen PY; Chen SM; Lu YJ; Lee ST
    Br J Neurosurg; 2012 Jun; 26(3):347-54. PubMed ID: 22168970
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro.
    Pötschke R; Gielen G; Pietsch T; Kramm C; Klusmann JH; Hüttelmaier S; Kühnöl CD
    Pediatr Res; 2020 Mar; 87(4):669-676. PubMed ID: 31756732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
    Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
    Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.
    Van Nifterik KA; Van den Berg J; Slotman BJ; Lafleur MV; Sminia P; Stalpers LJ
    J Neurooncol; 2012 Mar; 107(1):61-7. PubMed ID: 22037799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.